Profile data is unavailable for this security.
About the company
Novoprotein Scientific Inc is a China-based company mainly engaged in the provision of recombinant protein application solutions. The Company is mainly engaged in the research and development, production and sales of target and factor proteins, recombinant antibodies, enzymes and reagents, and the provision of related technical services. The Company's main products include novel coronavirus diagnostic antibodies, novel coronavirus diagnostic antigens, novel coronavirus pseudoviruses, novel coronavirus non-structural proteins and messenger ribonucleic acid (mRNA) raw materials enzymes and reagents. Its products and services are mainly used in biological medicine, basic research of life science, in vitro diagnosis, mRNA vaccine drugs and other fields. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)134.56m
- Net income in CNY-21.29m
- Incorporated2009
- Employees579.00
- LocationNovoprotein Scientific IncNo.12 Kechuang ParkNo.2358 Chang'an Road, Wujiang DistrictSUZHOU 215299ChinaCHN
- Phone+86 51 263919116
- Fax+86 51 263917398
- Websitehttps://www.novoprotein.com.cn/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hanshang Group Co Ltd | 1.28bn | -5.18m | 2.33bn | 2.38k | -- | 1.36 | -- | 1.83 | -0.016 | -0.016 | 4.31 | 5.80 | 0.362 | 2.52 | 8.04 | 536,620.30 | -0.4451 | 2.00 | -0.7501 | 3.89 | 53.60 | 57.24 | -1.23 | 4.89 | 0.2688 | 1.18 | 0.3163 | 15.03 | 0.1893 | 5.14 | -32.24 | 25.62 | 12.88 | -- |
| Novoprotein Scientific Inc | 134.56m | -21.29m | 2.56bn | 579.00 | -- | 1.19 | -- | 19.02 | -0.3031 | -0.3031 | 1.92 | 30.57 | 0.0592 | 0.5833 | 1.96 | 232,406.80 | -0.937 | -- | -0.959 | -- | 61.17 | -- | -15.82 | -- | 34.60 | -- | 0.0323 | -- | -42.09 | -- | -85.84 | -- | -- | -- |
| Ginwa Enterprise Group Inc | 581.53m | -15.51m | 2.56bn | 553.00 | -- | 1.69 | -- | 4.41 | -0.0382 | -0.0382 | 1.58 | 4.07 | 0.2968 | 4.81 | 5.28 | 1,051,591.00 | -0.7916 | 0.3641 | -0.9515 | 0.4141 | 76.18 | 73.64 | -2.67 | 1.15 | 2.19 | 0.196 | 0.0431 | 124.25 | -2.41 | -5.37 | -228.19 | -- | 61.66 | -- |
| Zhejiang Cheng Yi Pharmaceutical Co Ltd | 732.68m | 166.02m | 2.68bn | 738.00 | 16.17 | 2.16 | -- | 3.66 | 0.5072 | 0.5072 | 2.24 | 3.80 | 0.4013 | 2.01 | 17.68 | 992,793.70 | 9.07 | 12.01 | 11.17 | 14.75 | 66.13 | 69.79 | 22.60 | 22.84 | 1.01 | -- | 0.1998 | 36.44 | 2.54 | 4.24 | 0.8129 | 10.94 | -23.56 | 12.84 |
| Holder | Shares | % Held |
|---|---|---|
| Huashang Fund Management Co., Ltd.as of 30 Jun 2024 | 755.81k | 4.45% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 419.68k | 2.47% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024 | 252.75k | 1.49% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 19.46k | 0.12% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 16.13k | 0.10% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2024 | 7.00k | 0.04% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 4.30k | 0.03% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 2.59k | 0.02% |
| Golden Eagle Asset Management Co., Ltd.as of 30 Jun 2024 | 2.12k | 0.01% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 1.55k | 0.01% |
